EDITORIALS
Give me a sign, any sign
Correspondence to:
Correspondence to Dr P J Mazzone, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA; mazzonp@ccf.org
| The first 150 words of the full text of this article appear below. |
For clinical progress to occur in lung cancer, advances must be made in many inter-related areas. Advances in chemoprevention will be most useful if testing is able to identify those at greatest risk of developing lung cancer. Advances in surgical and ablative therapies will be most useful if testing is able to identify lung cancer at the earliest possible stage. Advances in systemic, targeted and individualised therapies will be most useful if testing is able to predict the nature of a patients lung cancer and the response to specific treatment choices.
A new test can improve on currently used tests by being more accurate, less invasive, less expensive and/or novel in its intent. To have a clinical impact, the result of the test must affect a decision to the benefit of the patient. The most recently developed tests that have had this sort of impact in lung cancer are positron
Relevant Articles
- Airwaves
- Wisia Wedzicha
Thorax 2009 64: i.[Extract] [Full Text] [PDF]
- Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study
- M Westhoff, P Litterst, L Freitag, W Urfer, S Bader, and J-I Baumbach
Thorax 2009 64: 744-748.[Abstract] [Full Text] [PDF]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
